These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 29282221)
1. Brain-Mimetic 3D Culture Platforms Allow Investigation of Cooperative Effects of Extracellular Matrix Features on Therapeutic Resistance in Glioblastoma. Xiao W; Zhang R; Sohrabi A; Ehsanipour A; Sun S; Liang J; Walthers CM; Ta L; Nathanson DA; Seidlits SK Cancer Res; 2018 Mar; 78(5):1358-1370. PubMed ID: 29282221 [TBL] [Abstract][Full Text] [Related]
3. Extracellular Hyaluronic Acid Influences the Efficacy of EGFR Tyrosine Kinase Inhibitors in a Biomaterial Model of Glioblastoma. Pedron S; Hanselman JS; Schroeder MA; Sarkaria JN; Harley BAC Adv Healthc Mater; 2017 Nov; 6(21):. PubMed ID: 28766870 [TBL] [Abstract][Full Text] [Related]
4. Bioengineered 3D brain tumor model to elucidate the effects of matrix stiffness on glioblastoma cell behavior using PEG-based hydrogels. Wang C; Tong X; Yang F Mol Pharm; 2014 Jul; 11(7):2115-25. PubMed ID: 24712441 [TBL] [Abstract][Full Text] [Related]
5. Bioengineered scaffolds for 3D culture demonstrate extracellular matrix-mediated mechanisms of chemotherapy resistance in glioblastoma. Xiao W; Wang S; Zhang R; Sohrabi A; Yu Q; Liu S; Ehsanipour A; Liang J; Bierman RD; Nathanson DA; Seidlits SK Matrix Biol; 2020 Jan; 85-86():128-146. PubMed ID: 31028838 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. McKinney A; Lindberg OR; Engler JR; Chen KY; Kumar A; Gong H; Lu KV; Simonds EF; Cloughesy TF; Liau LM; Prados M; Bollen AW; Berger MS; Shieh JTC; James CD; Nicolaides TP; Yong WH; Lai A; Hegi ME; Weiss WA; Phillips JJ Mol Cancer Ther; 2019 Sep; 18(9):1565-1576. PubMed ID: 31270152 [TBL] [Abstract][Full Text] [Related]
7. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588 [TBL] [Abstract][Full Text] [Related]
8. EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma. Gao M; Fu Y; Zhou W; Gui G; Lal B; Li Y; Xia S; Ji H; Eberhart CG; Laterra J; Ying M Cancer Res; 2021 Jul; 81(13):3580-3592. PubMed ID: 33910930 [TBL] [Abstract][Full Text] [Related]
9. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma. Liu X; Chen X; Shi L; Shan Q; Cao Q; Yue C; Li H; Li S; Wang J; Gao S; Niu M; Yu R J Exp Clin Cancer Res; 2019 May; 38(1):219. PubMed ID: 31122294 [TBL] [Abstract][Full Text] [Related]
10. A human co-culture cell model incorporating microglia supports glioblastoma growth and migration, and confers resistance to cytotoxics. Leite DM; Zvar Baskovic B; Civita P; Neto C; Gumbleton M; Pilkington GJ FASEB J; 2020 Jan; 34(1):1710-1727. PubMed ID: 31914660 [TBL] [Abstract][Full Text] [Related]
12. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma. Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558 [TBL] [Abstract][Full Text] [Related]
13. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. McNeill RS; Canoutas DA; Stuhlmiller TJ; Dhruv HD; Irvin DM; Bash RE; Angus SP; Herring LE; Simon JM; Skinner KR; Limas JC; Chen X; Schmid RS; Siegel MB; Van Swearingen AED; Hadler MJ; Sulman EP; Sarkaria JN; Anders CK; Graves LM; Berens ME; Johnson GL; Miller CR Neuro Oncol; 2017 Oct; 19(11):1469-1480. PubMed ID: 28379424 [TBL] [Abstract][Full Text] [Related]
14. The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells. Ramis G; Villalonga-Planells R; Serra-Sitjar M; Brell M; Fernández de Mattos S; Villalonga P Cell Oncol (Dordr); 2019 Aug; 42(4):521-536. PubMed ID: 30980364 [TBL] [Abstract][Full Text] [Related]
15. A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling. Wu ATH; Huang HS; Wen YT; Lawal B; Mokgautsi N; Huynh TT; Hsiao M; Wei L Cells; 2021 Sep; 10(9):. PubMed ID: 34572040 [TBL] [Abstract][Full Text] [Related]
16. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399 [TBL] [Abstract][Full Text] [Related]
17. Hyaluronic-Acid Based Hydrogels for 3-Dimensional Culture of Patient-Derived Glioblastoma Cells. Xiao W; Ehsanipour A; Sohrabi A; Seidlits SK J Vis Exp; 2018 Aug; (138):. PubMed ID: 30199037 [TBL] [Abstract][Full Text] [Related]
18. Culture on 3D Chitosan-Hyaluronic Acid Scaffolds Enhances Stem Cell Marker Expression and Drug Resistance in Human Glioblastoma Cancer Stem Cells. Wang K; Kievit FM; Erickson AE; Silber JR; Ellenbogen RG; Zhang M Adv Healthc Mater; 2016 Dec; 5(24):3173-3181. PubMed ID: 27805789 [TBL] [Abstract][Full Text] [Related]
19. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808 [TBL] [Abstract][Full Text] [Related]
20. A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses. Gomez-Roman N; Stevenson K; Gilmour L; Hamilton G; Chalmers AJ Neuro Oncol; 2017 Feb; 19(2):229-241. PubMed ID: 27576873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]